Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer.
Geurs
F
F
Department of Oncology, RZ Sint-Maria, Halle, Belgium. G@regzhsintmaria.bel
Vandewaeter
S
S
Ponette
S
S
Ponette
J
J
Knape
S
S
Demetter
P
P
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000473:pathology*; D006801:Humans; D000077146:Irinotecan; D008107:Liver Diseases / Q000188:drug therapy* / Q000209:etiology; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D011799:Quinazolines / Q000008:administration & dosage; D013876:Thiophenes / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D011799:Quinazolines; D013876:Thiophenes; D000077146:Irinotecan; C068874:raltitrexed; D000068818:Cetuximab; D002166:Camptothecin